Literature DB >> 25915910

Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma.

Marcus C B Tan1, Murray F Brennan, Deborah Kuk, Narasimhan P Agaram, Cristina R Antonescu, Li-Xuan Qin, Nicole Moraco, Aimee M Crago, Samuel Singer.   

Abstract

OBJECTIVE: To determine the prognostic significance of histologic type/subtype in a large series of patients with primary resected retroperitoneal sarcoma.
BACKGROUND: The histologic diversity and rarity of retroperitoneal sarcoma has hampered the ability to predict patient outcome.
METHODS: From a single-institution, prospective database, 675 patients treated surgically for primary, nonmetastatic retroperitoneal sarcoma during 1982 to 2010 were identified and histologic type/subtype was reviewed. Clinicopathologic variables were analyzed for association with disease-specific death (DSD), local recurrence (LR), and distant recurrence (DR).
RESULTS: Median follow-up for survivors was 7.5 years. The predominant histologies were well-differentiated liposarcoma, dedifferentiated liposarcoma, and leiomyosarcoma. Five-year cumulative incidence of DSD was 31%, and factors independently associated with DSD were R2 resection, resection of 3 or more contiguous organs, and histologic type. Five-year cumulative incidence for LR was 39% and for DR was 24%. R1 resection, age, tumor size, and histologic type were independently associated with LR; size, resection of 3 or more organs, and histologic type were independently associated with DR. Liposarcoma and leiomyosarcoma were associated with late recurrence and DSD (as long as 15 years from diagnosis). For solitary fibrous tumor, LR was uncommon (<10%), but early distant recurrence was common (36% at 5 years). Nomograms were developed to predict DSD, LR, and DR.
CONCLUSIONS: Histologic type/subtype is the most important independent predictor of DSD, LR, and DR in primary retroperitoneal sarcoma. Histology predicts the pattern and incidence of LR and DR and will aid in more accurate patient counseling and selection of patients for adjuvant therapy trials.

Entities:  

Mesh:

Year:  2016        PMID: 25915910      PMCID: PMC4619189          DOI: 10.1097/SLA.0000000000001149

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  32 in total

1.  Core needle biopsy for diagnosis of extremity soft tissue sarcoma.

Authors:  M J Heslin; J J Lewis; J M Woodruff; M F Brennan
Journal:  Ann Surg Oncol       Date:  1997 Jul-Aug       Impact factor: 5.344

2.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk.

Authors:  Kimberly Moore Dalal; Michael W Kattan; Cristina R Antonescu; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

4.  Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.

Authors:  Jean-Michel Coindre; Odette Mariani; Frédéric Chibon; Aline Mairal; Nicolas De Saint Aubain Somerhausen; Elizabeth Favre-Guillevin; Nguyen Binh Bui; Eberhard Stoeckle; Isabelle Hostein; Alain Aurias
Journal:  Mod Pathol       Date:  2003-03       Impact factor: 7.842

5.  Validation of the postoperative nomogram for 12-year sarcoma-specific mortality.

Authors:  Fritz C Eilber; Murray F Brennan; Frederick R Eilber; Sarah M Dry; Samuel Singer; Michael W Kattan
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

6.  Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system.

Authors:  Luigi Mariani; Rosalba Miceli; Michael W Kattan; Murray F Brennan; Maurizio Colecchia; Marco Fiore; Paolo G Casali; Alessandro Gronchi
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

7.  Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

Authors:  Samuel Singer; Cristina R Antonescu; Elyn Riedel; Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

8.  A competing-risks nomogram for sarcoma-specific death following local recurrence.

Authors:  Michael W Kattan; Glenn Heller; Murray F Brennan
Journal:  Stat Med       Date:  2003-11-30       Impact factor: 2.373

Review 9.  Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.

Authors:  J J Lewis; D Leung; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.

Authors:  Samuel Singer; Nicholas D Socci; Grazia Ambrosini; Elliot Sambol; Penelope Decarolis; Yuhsin Wu; Rachael O'Connor; Robert Maki; Agnes Viale; Chris Sander; Gary K Schwartz; Cristina R Antonescu
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  56 in total

1.  Retroperitoneal Sarcomas: Prognostic Factors and Outcomes of a Series of Patients Treated at a Single Institution.

Authors:  Shraddha Patkar; Abhay K Kattepur; Rajesh Shinde; Mahesh Goel
Journal:  Indian J Surg Oncol       Date:  2020-01-15

2.  An Evaluation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) Staging System for Retroperitoneal Sarcomas Using the National Cancer Data Base (NCDB): Does Size Matter?

Authors:  Sarah B Fisher; Yi-Ju Chiang; Barry W Feig; Janice N Cormier; Kelly K Hunt; Keila E Torres; Christina L Roland
Journal:  Am J Clin Oncol       Date:  2019-02       Impact factor: 2.339

Review 3.  [Intra-abdominal and retroperitoneal sarcomas].

Authors:  J Kirchberg; J Weitz
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

4.  A novel nomogram for predicting local recurrence-free survival after surgical resection for retroperitoneal liposarcoma from a Chinese tertiary cancer center.

Authors:  Guoqiang Xue; Zhen Wang; Chengpeng Li; Ang Lv; Xiuyun Tian; Jianhui Wu; Hui Qiu; Chunyi Hao
Journal:  Int J Clin Oncol       Date:  2020-10-17       Impact factor: 3.402

5.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group.

Authors: 
Journal:  Ann Surg Oncol       Date:  2016-08-01       Impact factor: 5.344

6.  Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center.

Authors:  Naruhiko Ikoma; Christina L Roland; Keila E Torres; Yi-Ju Chiang; Wei-Lien Wang; Neeta Somaiah; Gary N Mann; Kelly K Hunt; Janice N Cormier; Barry W Feig
Journal:  J Surg Oncol       Date:  2017-12-11       Impact factor: 3.454

7.  Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit.

Authors:  Naruhiko Ikoma; Christina L Roland; Keila E Torres; Yi-Ju Chiang; Wei-Lien Wang; Neeta Somaiah; Gary N Mann; Kelly K Hunt; Janice N Cormier; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2018-03-08       Impact factor: 5.344

8.  Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery.

Authors:  Naruhiko Ikoma; Keila E Torres; Heather Y Lin; Vinod Ravi; Christina L Roland; Gary N Mann; Kelly K Hunt; Janice N Cormier; Barry W Feig
Journal:  J Surg Oncol       Date:  2017-05-29       Impact factor: 3.454

9.  Liver-directed treatments of liver-dominant metastatic leiomyosarcoma.

Authors:  Hailey Krzyston; Brian Morse; Danielle Deperalta; Anupam Rishi; Roger Kayaleh; Ghassan El-Haddad; Johnna Smith; Mihaela Druta; Bela Kis
Journal:  Diagn Interv Radiol       Date:  2020-09       Impact factor: 2.630

Review 10.  [Complex pelvic and sarcoma surgery with vascular replacement].

Authors:  S Pistorius; Ch Reeps; J Weitz
Journal:  Chirurg       Date:  2016-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.